Associate Professor / Group Leader Proteomics
Dr. Peter van Veelen
RESEARCH
The research of Peter van Veelen revolves around method development to improve the depth of identification of proteomes and HLA-peptidomes to enable a better understanding of mechanisms in health and disease. The former in close collaboration with the departments of Hematology, Immunology, Rheumatology and Cell Biology. This has led among others to the unravelling of mechanisms underlying coeliac disease, the elucidation of relevant epitopes that can be used in cancer immunotherapy, improved diagnostics in rheumatoid arthritis, and elucidation of mechanisms in antigen processing.
CURRICULUM VITAE
- Peter van Veelen studied chemistry, with a specialization in mass spectrometry at the University of Amsterdam (UvA) and obtained his PhD in 1994 (Thesis title: Analysis of Biomacromolecules Plasma Desorption mass spectrometry and MatrixAssisted Laser Desorption Ionization Mass Spectrometry) from Leiden University. Following a short period at Organon as senior scientist mass spectrometry, he returned to the LUMC/Leiden University in 1996 to set up a proteomics group at the Immunology department with a strong focus on HLA-peptidomics. In 2016 the group integrated with the newly formed CPM. He is currently heading the Proteomics group.
Next to HLA-peptidomics the Proteomics group is continuously involved in a wide array of collaborative proteomics projects, and consortia, both inside and outside the LUMC, also including projects with industrial partners. Much work has been done in the fields of cancer, hematology, immunology, rheumatology, coeliac disease, diabetes and cell biology.
Publications
-
The human leukocyte antigen-presented ligandome of B lymphocytes.
Hassan C, Kester MG, de Ru AH, Hombrink P, Drijfhout JW, Nijveen H, Leunissen JA, Heemskerk MH, Falkenburg JH, van Veelen PA
Mol Cell Proteomics. 2013 Jul;12(7):1829-43. doi: 10.1074/mcp.M112.024810. Epub 2013 Mar 12.PMID: 23481700
-
Small-Molecule Activity-Based Probe for Monitoring Ubiquitin C-Terminal Hydrolase L1 (UCHL1) Activity in Live Cells and Zebrafish Embryos.
Kooij R, Liu S, Sapmaz A, Xin BT, Janssen GMC, van Veelen PA, Ovaa H, Dijke PT, Geurink PP
J Am Chem Soc. 2020 Sep 30;142(39):16825-16841. doi: 10.1021/jacs.0c07726. Epub 2020 Sep 18. PMID: 32886496
-
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M
J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14. PMID: 30640174
Groups:
Proteomics
